CD274 and neoplasm: In regard to systemic therapy/TACE combinations, multiple critical questions persist, particularly pertaining to the identification of predictive factors (such as treatment-related adverse events, PD-L1 expression, or tumor mutational burden) to effectively select patients suitable for combined locoregional therapies and immunotherapy.